Literature DB >> 11206020

Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry.

C B Granger1.   

Abstract

An abundance of evidence is available from large, randomized clinical trials supporting the efficacy of therapies for the management of patients with acute coronary syndromes. For ST-segment elevation myocardial infarction (MI), a variety of databases can be used to assess how these therapies, both pharmacologic and invasive, are being integrated into real practice. Little information is available, however, with regard to how newer treatments are actually being implemented for patients with unstable angina and non-ST-segment elevation MI. There are several important issues to consider in evaluating current treatment practices for acute coronary syndromes, including limitations of clinical trial databases, a trend toward progressive shortening of length of hospital stay, and variations in the availability of resources among treatment centers. In response to the need for a broader database that would address the global impact of clinical management practices in acute coronary syndromes, the Global Registry of Acute Coronary Events (GRACE) Registry has been established. The GRACE Registry will initially collect data on patient care from a variety of treatment centers in 14 countries, the plan being to eventually enroll 10,000 patients per year. This international observational database will obtain information on the complete spectrum of acute coronary syndromes, with the specific goals of describing diagnostic and treatment strategies, determining hospital outcomes, improving quality of care, and developing hypotheses for future clinical research.

Entities:  

Mesh:

Year:  2000        PMID: 11206020     DOI: 10.1016/s0002-9149(00)01475-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Gender differences in contrast-enhanced magnetic resonance imaging after acute myocardial infarction.

Authors:  Birgit Langhans; Tareq Ibrahim; Jörg Hausleiter; Carolin Sonne; Stefan Martinoff; Albert Schömig; Martin Hadamitzky
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-09       Impact factor: 2.357

2.  Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.

Authors:  M Janzon; L-A Levin; E Swahn
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

3.  Inter-hospital transfers and door-to-balloon times for STEMI: a single centre cohort study.

Authors:  René Forsyth; Zhong-Hua Sun; Christopher Reid; Rachael Moorin
Journal:  J Geriatr Cardiol       Date:  2020-06       Impact factor: 3.327

4.  2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards).

Authors:  Christopher P Cannon; Ralph G Brindis; Bernard R Chaitman; David J Cohen; J Thomas Cross; Joseph P Drozda; Francis M Fesmire; Dan J Fintel; Gregg C Fonarow; Keith A Fox; Darryl T Gray; Robert A Harrington; Karen A Hicks; Judd E Hollander; Harlan Krumholz; Darwin R Labarthe; Janet B Long; Alice M Mascette; Connie Meyer; Eric D Peterson; Martha J Radford; Matthew T Roe; James B Richmann; Harry P Selker; David M Shahian; Richard E Shaw; Sharon Sprenger; Robert Swor; James A Underberg; Frans Van de Werf; Bonnie H Weiner; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2013-01-28       Impact factor: 24.094

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.